The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
The firm said that it may use some of the net proceeds to acquire or invest in complementary businesses and technologies.
The company, based in Fort Myers, Florida, said that it plans to use the net proceeds from the offering for general corporate purposes.
The firm's clinical service revenues were up also 51 percent, and it also announced it has signed a contract with insurer Humana.
The companies were involved in a dispute over NeoGenomics' handling of Health Discovery technology it licensed in 2012 to develop cancer tests.
Test volumes, revenues per test and costs per test improved during the quarter, company executives said.
The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.
A brief recap of Genetics/Genomics news the week of Dec 14, 2018: AstraZeneca, NeoGenomics, Fluidigm, Luminex, Petco Foundation, and SQI Diagnostics
Qiagen will provide IUO tests for NeoGenomics to verify, set up, and run in clinical trials and in anticipation of regulatory approval.
After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.